Lescarden expands ICN deal to cover Canada:
This article was originally published in Clinica
Executive Summary
ICN Canada, of Montreal, Quebec, has been granted a 10-year exclusive licence to market New York-based Lescarden's Catrix wound dressing in Canada. The product, which is a specially processed bovine cartilage product in fine-powder form, is FDA-approved for the management of chronic skin wounds including decubitus ulcers, venous stasis ulcers and diabetic ulcers, as well as second degree burns and post-radiation dermatitis. The total market is estimated at some $10bn worldwide. ICN Iberica already sells the product in Spain and Portugal.